Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.

"Potential Conflicts of Interest The authors declared no conflict of interest."

"This work was funded by the Michael J. Fox Foundation for Parkinson's Research (MJFF; grant #11849) to M.J.‐M. and E.T., and (grant #MJFF‐000858) to R.F‐S., M.E., and C.M. G.C. was funded by a FI‐2021 grant from the Agència de Gestió d'Ajuts Universitaris de Recerca (AGAUR; grant #FI‐B‐00378). J.S. was funded by a FPU grant from the Spanish Ministry of Science, Innovation and Universities (MICIU; grant #FPU18/00194). M.F. was funded through a María de Maeztu grant (grant #MDM‐2017‐0729) to the Parkinson Disease and Movement Disorders Group of the Institut de Neurociències (Universitat de Barcelona). E.P. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grant # PID2019‐106447RB‐100). J.A. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grants #SAF2017‐88076 and #PID2020‐119386R‐100). C.M. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grants #SAF2017‐88812‐R and PID2020‐119236RB‐I00). R.F‐S. was supported by a Miguel Servet grant (grant #CP19/00048) and an FIS grant (grant #CP19/00048) from the Instituto de Salud Carlos III (ISCIII) co‐funded by the European Union, and a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI; AEI/FEDER/UE; grant #SAF2015‐73508‐JIN). IDIBAPS receives support from the CERCA programme of Generalitat de Catalunya."